Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-TNF-alpha therapies: they are all the same (aren't they?).

× No keyword cloud information.

29 in total

1. Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.

Authors: Wenhui Hu; Hantamalala Ralay Ranaivo; Saktimayee M Roy; Heather A Behanna; Laura K Wing; Lenka Munoz; Ling Guo; Linda J Van Eldik; D Martin Watterson
Journal: Bioorg Med Chem Lett Date: 2006-10-17 Impact factor: 2.823

Review 2. Biological therapy for dermatological manifestations of inflammatory bowel disease.

Authors: Maddalena Zippi; Roberta Pica; Daniela De Nitto; Paolo Paoluzi
Journal: World J Clin Cases Date: 2013-05-16 Impact factor: 1.337

3. In vitro TNF blockade enhances ex vivo expansion of regulatory T cells in patients with immune thrombocytopenia.

Authors: Hui Zhong; James Bussel; Karina Yazdanbakhsh
Journal: Br J Haematol Date: 2014-09-24 Impact factor: 6.998

4. Treatment for Rheumatoid Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis.

Authors: Richard C Chou; Michael Kane; Sanjay Ghimire; Shiva Gautam; Jiang Gui
Journal: CNS Drugs Date: 2016-11 Impact factor: 5.749

5. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.

Authors: Florenzo Iannone; Francesco Trotta; Carlomaurizio Montecucco; Carlomaurizio Monteccuco; Roberto Giacomelli; Mauro Galeazzi; Marco Matucci-Cerinic; Clodoveo Ferri; Maurizio Cutolo; Lisa Maria Bambara; Giovanni Triolo; Gianfranco Ferraccioli; Gabriele Valentini; Giovanni Lapadula
Journal: Ann Rheum Dis Date: 2006-07-12 Impact factor: 19.103

6. Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).

Authors: Liisa M Virkki; Heikki Valleala; Yuya Takakubo; Jorma Vuotila; Heikki Relas; Riitta Komulainen; Riitta Koivuniemi; Urpo Yli-Kerttula; Markku Mali; Susanna Sihvonen; Maija-Liisa Krogerus; Eero Jukka; Satu Nyrhinen; Yrjö T Konttinen; Dan C Nordström
Journal: Clin Rheumatol Date: 2011-06-07 Impact factor: 2.980

7. Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis.

Authors: Pinar Karaca-Mandic; Geoffrey F Joyce; Dana P Goldman; Marianne Laouri
Journal: Health Serv Res Date: 2010-10 Impact factor: 3.402

8. Tissue-Engineered Regeneration of Hemisected Spinal Cord Using Human Endometrial Stem Cells, Poly ε-Caprolactone Scaffolds, and Crocin as a Neuroprotective Agent.

Authors: Panieh Terraf; Shideh Montasser Kouhsari; Jafar Ai; Hamideh Babaloo
Journal: Mol Neurobiol Date: 2016-09-13 Impact factor: 5.590

Review 9. Perspectives of pharmacological treatment in otosclerosis.

Authors: Balázs Liktor; Zoltán Szekanecz; Tamás József Batta; István Sziklai; Tamás Karosi
Journal: Eur Arch Otorhinolaryngol Date: 2012-07-29 Impact factor: 2.503

10. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up.

Authors: Stacy P Ardoin; Deborah Kredich; Egla Rabinovich; Laura E Schanberg; Glenn J Jaffe
Journal: Am J Ophthalmol Date: 2007-10-22 Impact factor: 5.258